DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Turner NC, Balmana J, Domchek SM et al.
A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study). San Antonio Breast Cancer Symposium 2014; Abstract No. OT1-1 – 14.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.